Having trouble accessing articles? Reset your cache.

CAR T strategies for cracking the code in solid tumors

The targets and indications CAR T developers are exploring to get to efficacy in solid tumors

As drug developers try to crack the code for making CAR T cell therapies work in solid tumors, they aren’t sticking to the playbook that led to success with other modalities. BioCentury’s analysis of the CAR T pipeline finds companies are exploring a wide range of not-yet-validated targets and historically tough indications.

CAR T therapies for solid tumors have lagged those for hematologic malignancies for a constellation of reasons, including intratumoral heterogeneity, lack of tumor-specific target antigens, and an immunosupressive microenvironment.

Dozens of companies aim to break through those barriers to bring the high response rates seen in blood cancers to solid

Read the full word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers